Recent Analysts’ Ratings Changes for Cencora (COR)

A number of firms have modified their ratings and price targets on shares of Cencora (NYSE: COR) recently:

• 10/30/2025 – Cencora had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/30/2025 – Cencora had its price target raised by analysts at Mizuho from $334.00 to $340.00. They now have an “outperform” rating on the stock.
• 10/27/2025 – Cencora had its price target raised by analysts at UBS Group AG from $350.00 to $380.00. They now have a “buy” rating on the stock.
• 10/16/2025 – Cencora had its price target raised by analysts at Mizuho from $316.00 to $334.00. They now have an “outperform” rating on the stock.
• 10/11/2025 – Cencora was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/8/2025 – Cencora was given a new $340.00 price target on by analysts at Evercore ISI.
• 10/8/2025 – Cencora had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Cencora had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.